DailyIQ
|
Sector:HealthcareAll sectors
Last updated 27 minutes ago

VTRS·Viatris Inc.

$.
-. (-.%)
High
$16.41
Open
$16.34
Market Cap
19.15B
52W High
$17.53
Low
$15.95
P. Close
$16.34
P/E
-
52W Low
$8.63
Fwd P/E
6.13
DailyIQ Est.
$18.51
Technical Score (1D)
77
BUY
News Sentiment
50
MIXED
The most recent catalyst for Viatris is the expectation of three FDA PDUFA decisions before the end of 2026, which could unlock new product approvals and broaden the company’s revenue base. These pending decisions are tied to the company’s recent Phase 3 success for VR‑205 in Japanese IgA nephropathy, which has already met primary and key secondary endpoints and demonstrated a 33‑plus percent reduction in proteinuria. The FDA approvals would likely accelerate the planned NDA filing in Japan by the end of 2026, positioning VR‑205 as the first targeted‑release budesonide for IgA nephropathy and potentially opening a sizable specialty nephrology market. In parallel, Viatris secured a ¥40 billion senior unsecured term loan from Mizuho Bank, providing liquidity to refinance existing debt and support general corporate purposes while imposing covenants that limit dividend payments and mergers. The loan’s TIBO‑plus‑1.10% rate and three‑year maturity give the company financial flexibility to invest in commercialization of VR‑205 and other pipeline assets without compromising its credit rating. Viatris also refinanced a $247.7 million term loan, extending its maturity and reducing interest costs, which improves cash‑flow and supports dividend policy at the current 7 % yield. With the Q2 2026 earnings release scheduled for August 6, analysts will scrutinize how the new approvals and financing affect revenue, earnings per share, and guidance for the remainder of the fiscal year. Over the next 1–10 trading days, traders should monitor the exact dates of the FDA PDUFA decisions, any updates on the commercial rollout of VR‑205, and the company’s debt covenant compliance following the new loan. Additionally, watch for the company’s earnings call on August 6 for commentary on product mix, pricing, and cost structure changes that could influence future profitability. Finally, keep an eye on regulatory review timelines in Japan, as a favorable decision could accelerate market entry and materially impact Viatris’s valuation trajectory.
Earnings Summary
Viatris Inc. is a global healthcare company that develops, manufactures, and distributes prescription brand drugs, generic drugs, complex generics, and biosimilars across North America, Europe, China, and emerging markets, positioning itself within the specialty and generic drug manufacturing sector. In the most recent two quarters—Q4 2025 and Q1 2026—the company reported EPS of $0.57 and $0.59, respectively, a modest $0.02 uptick from the prior quarter, while revenue fell from $3.70 billion to $3.52 billion, reversing the upward trajectory seen in Q2 2025 ($3.58 billion) and Q3 2025 ($3.76 billion); EPS and revenue growth have therefore decelerated, with the company beating analyst estimates in four of the last six quarters but missing in Q4 2024 and Q1 2026. Historically, Viatris has maintained a pattern of revenue beats, with Q4 2025 and Q1 2026 both surpassing guidance, and a mixed EPS record that has generally trended upward except for the two recent misses, indicating a consistent ability to generate revenue above expectations even as earnings margin pressures surface. Recent news highlights the firm’s outperformance relative to peers, driven by rising mandate sales and a robust pipeline, and underscores strategic pivots toward higher‑margin generics, biosimilars, and specialty drugs; the FDA acceptance of a fast‑acting non‑opioid meloxicam NDA and a euro‑denominated senior unsecured note issuance further signal momentum in product development and financial flexibility. Investors should watch the forthcoming Q4 earnings guidance for updates on mandate sales, pipeline milestones, and the impact of the new debt structure on interest expense, as well as regulatory developments surrounding the meloxicam NDA and any commentary on workforce initiatives tied to the 2026 Best Workplace award, all of which could materially influence the company’s valuation narrative in the near term.

EPS

EstBeatMiss
$0.47$0.52$0.58$0.64$0.70Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.60 - -
Q1'26$0.61$0.59-3.4%
Q4'25$0.55$0.57+3.4%
Q3'25$0.62$0.67+8.5%
Q2'25$0.56$0.62+11.6%
Q1'25$0.49$0.50+1.6%

Revenue

EstBeatMiss
$3.2B$3.3B$3.5B$3.7B$3.8BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.7B - -
Q1'26$3.4B$3.5B+2.7%
Q4'25$3.3B$3.7B+10.7%
Q3'25 - $3.8B -
Q2'25 - $3.6B -
Q1'25 - $3.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

VTRS Stock Snapshot

VTRS is currently trading at $16.07, giving Viatris Inc. a market cap of 19.15B. Today's range spans $15.95–$16.41, with shares opening at $16.34 and moving down $0.27 (1.7%) from the prior close. DailyIQ's technical score sits at 77/100 (BUY) with a news sentiment reading of 50/100.

Over the past year VTRS has traded between $8.63 and $17.53 - the current price is +86.2% off the 52-week low and -8.3% from the high. 18 analysts cover the stock with a Buy consensus and a mean 12-month target of $17.81 (range $12.00–$23.00), implying upside of +10.8%.

Algorithmic and quant fund activity in VTRS tends to intensify when the technical score crosses the 77/100 threshold - systematic models in large-cap Healthcare names trigger entry signals at these levels, adding momentum to what may have started as fundamental-driven buying. Signal: BUY. Sentiment: neutral (50/100). Price: $16.07 (in the upper portion of its 52-week range). Annual range: $8.63–$17.53.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (77/100) and news sentiment (50/100, neutral) supports the narrative, analyst upgrades follow price rather than lead it. At $16.07 (in the upper portion of its 52-week range), VTRS's position within the $8.63–$17.53 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.